Arkolith/Insider Trading/TBPH/Form 4

Broshy Eran

DirectorTheravance Biopharma, Inc. (TBPH) · full profile →Form 4 · filed Dec 1, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$590K
Net Open-Market Flow
-$590K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 26, 2025Sell(S)16K$20.00$310K45K
Nov 26, 2025Sell(S)14K$20.00$280K60K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 26, 2025Option exercise(M)14K$10.15$142K82K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001256230-25-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML